This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
NanoViricides, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023 CI
NanoViricides, Inc. Announces Clinical Trial Demonstration of Safety and Tolerability of NV-CoV-2 Has Implications Beyond COVID Treatment, Explains NanoViricides - NV-387 Could be As Revolutionary as Antibiotics CI
Nanoviricides, Inc. Reports Safety in Multiple-Ascending-Dose Healthy Subjects Clinical Trial Part Successfully Established for the Nanoviricides Ultra-Broad-Spectrum Antiviral Drug Nv-2 with No Adverse Events Found CI
NanoViricides, Inc. Announces the Single-Ascending Dose Part of the Phase 1A/1B Human Clinical Trial of NV-CoV-2 CI
NanoViricides, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023 CI
Nanoviricides, Inc. Announces Broad-Spectrum Antiviral Nv-387 (Nv-Cov-2) in Phase 1A/1B Clinical Trial Is Highly Effective in an Animal Model for Mpox and Smallpox Drug Development CI
North American Morning Briefing : Geopolitical -2- DJ
NanoViricides, Inc. Reports Earnings Results for the Full Year Ended June 30, 2023 CI
North American Morning Briefing : Stock Futures -2- DJ
Nanoviricides, Inc. Reports the Phase 1A/1B Human Clinical Trial of Nv-Cov-2 CI
Health Care Down on Cyclical Rotation -- Health Care Roundup DJ
Nanoviricides, Inc.'S Broad-Spectrum Antiviral NV-387 Has Demonstrated Excellent Effectiveness in RSV in A Lethal Lung Disease Animal Model, Reports Nanoviricides CI
Nanoviricides, Inc. Reports Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 Is Progressing Well CI
Nanoviricides, Inc. Announces Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun CI
NanoViricides, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023 CI
NanoViricides Files $150 Million Mixed Shelf MT
NanoViricides, Inc. Enters into License Agreement with Karveer Meditech Private Limited CI
EF Hutton Lowers Price Target on NanoViricides to $5.25 From $8.50, Maintains Buy Rating MT
NanoViricides, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2022 CI
North American Morning Briefing : Stock Futures -3- DJ
NanoViricides, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2022 CI
NanoViricides Expects to Have Sufficient Funds to Complete Human Trials for Lead COVID-19 Drug Candidate MT
NanoViricides, Inc. Reports Earnings Results for the Full Year Ended June 30, 2022 CI
North American Morning Briefing : Treasury Yield -2- DJ
Sector Update: Health Care Stocks Slipping Ahead of Thursday Close MT
Chart NanoViricides, Inc.
More charts
NanoViricides, Inc. is a development stage company, which is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Its lead drug candidate is NV-CoV-2 (API NV-387) for the treatment of COVID-19 disease caused by SARS-CoV-2 coronavirus. Its other advanced candidate is NV-HHV-1 for the treatment of Shingles. NV-CoV-2 is its nanoviricide drug candidate for COVID-19 containing the nanoviricide API, NV-387. NV-CoV-2-R is its other drug candidate for COVID-19, which is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. It has developed both of its own drug candidates, NV-CoV-2 and NV-CoV-2-R independently. It is also developing drugs against a number of viral diseases, including RSV, oral and genital Herpes, viral diseases of the eye, including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu and others.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.11 USD
Average target price
6.5 USD
Spread / Average Target
+485.59%
Consensus
  1. Stock Market
  2. Equities
  3. NNVC Stock
  4. News NanoViricides, Inc.
  5. NanoViricides : Says its Drug Candidate was Found Effective Against Covid-19 Including Variants